Menu ×

HEALTHCARE & PHARMACEUTICAL

CDK 4/6 Inhibitor Drugs Market Segmentation by Drug Type {Palbociclib (Ibrance), Ribociclib (Kisqali), and Abermaciclib (Verzenio)}; by Patient (Pre-Menopausal, Post-Menopausal, and Others); by End-Users (Hospitals, Clinics, Research Laboratories, and Retail Pharmacies) – Global Demand Analysis & Opportunity Outlook 2020-2030

  • Text Size:

Extensive insights into the Growth of CDK 4/6 Inhibitor Drugs Market amidst COVID-19

Get the detailed impact analysis of COVID-19 that has disrupted the entire world and affected many industries.

Request Insights


IN THE NEWS

  • April 4, 2019: Pfizer Inc. released a statement stating that the United States Food and Drug Administration (FDA), has approved Ibrance (palbociclib) for the treatment of HR+, HER2– metastatic breast cancer in men.

  • October 13, 2021: Eli Lilly and Company announced that the United States Food and Drug Administration (FDA), has approved Verzenio (abemaciclib) for the treatment of adult patients with HR+, HER2-, node-positive, EBC, and a Ki-67 score of ≥20% breast cancer.

Global CDK 4/6 Inhibitor Drugs Market Highlights Over 2020 - 2030

The global CDK 4/6 inhibitor drugs market is estimated to garner a revenue of USD 42511.38 Million by the end of 2030 by growing at a CAGR of 13.2% over the forecast period, i.e., 2021 – 2030. Moreover, in the year 2020, the market registered a revenue of USD 6991.70 Million. The growth of the market can be attributed to rising prevalence of breast cancer worldwide, and the growing need for advanced screening and treatment to cure the disease at an early stage. According to the statistics by the World Bank, 2.3 Million women were diagnosed with breast cancer in the year 2020. Moreover, in the same year, 685000 number of deaths caused due to breast cancer were registered. Besides this, owing to the rising advancements in the treatment of hormone receptor (HR) positive breast cancer, it has been observed that the CDK 4/6 inhibitor drugs have displayed good results as compared to other treatment methods. Hence, this drug has been highly preferred by oncologists for the treatment of breast cancer.

CDK 4/6 Inhibitor Drugs Market Graph

Additionally, the increasing advancements in the research and development of advanced drugs for the treatment and cure of breast cancer, is also expected to create numerous opportunities for the market growth. Backed by the surge in investment in the development of cancer drugs, the demand for CDK 4/6 inhibitor drugs is expected to grow remarkably, and in turn, boost the market growth. According to the statistics by the National Institute of Health (NIH), the research funding budget for breast cancer in the United States grew from USD 657 Million in the year 2013 to USD 788 Million in the year 2020. This is further projected to increase to USD 803 Million and USD 834 Million in the year 2021 and 2022 respectively.CLICK TO DOWNLOAD SAMPLE REPORT

Global CDK 4/6 Inhibitor Drugs Market Regional Synopsis

Regionally, the global CDK 4/6 inhibitor drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America region is anticipated to garner the largest revenue of USD 30204.34 Million by the end of 2030, up from a revenue of USD 4992.07 Million in the year 2020. The growth of the market in the region can be attributed to the presence of a strong healthcare network, rising awareness for breast cancer amongst women, and the increasing need amongst the cancer patients to diagnose and treat the disease. According to the International agency for Research on Cancer (GLOBOCAN) of the World Health Organization (WHO), the estimated number of deaths caused due to breast cancer amongst women in North America is expected to grow from 48.4 Thousands in the year 2020 to 67.2 Thousands in the year 2040.

On the other hand, the market in Europe is expected to generate the second largest revenue of USD 6929.36 Million by the end of 2030. The market in the region is further segmented by country into the United Kingdom, Germany, Italy, France, Spain, Russia, Netherlands, and the Rest of Europe. Out of these, the market in Germany is expected to generate the largest revenue of USD 1434.38 Million by the end of 2030, by growing from a revenue of USD 229.93 Million in the year 2020.

The study further incorporates Y-O-Y Growth, market opportunities, demand & supply and forecast future opportunity in North America (United States, Canada, Mexico), South America, Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).

Growth Drivers and Challenges Impacting the Growth of the Global CDK 4/6 Inhibitor Drugs Market

Growth Drivers

  • Rising Prevalence of Breast Cancer
  • Increasing Advancements in Cancer Research

Challenges

  • High Cost of the Drug
  • Concern for the Side Effects Associated with the Drug

Global CDK 4/6 Inhibitor Drugs Market Segmentation Synopsis

The global CDK 4/6 inhibitor drugs market is segmented by drug type into palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio). Out of these, the palbociclib (Ibrance) segment is expected to generate the largest revenue of USD 37659.17 Million by the end of 2030, up from a revenue of USD 5391.08 Million in the year 2020. Moreover, the segment is also expected to grow with the highest CAGR of 13.4% during the forecast period. By patient, the market is segmented into pre-menopausal, post-menopausal, and others. Out of these, the post-menopausal segment is expected to generate the largest revenue of USD 35794.04 Million by the end of 2030. By end-users, the market is further segmented into hospitals, clinics, research laboratories, and retail pharmacies. Out of these, the hospitals segment is expected to garner the highest market share by the end of 2030 and also attain the largest revenue of USD 24344.17 Million in the same year.

Key Companies Dominating the Market

Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global CDK 4/6 inhibitor drugs market that are included in our report are Pfizer Inc., Novartis AG, Eli Lilly and Company, and others.

Key Reasons to Buy Our Report

  • The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
  • It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
  • The report includes detailed company profiles of the major players dominating the market.
  • We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
  • We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.

FREQUENTLY ASKED QUESTIONS

Global CDK 4/6 Inhibitor Drugs Market TOC

  1. Market Definition and Research Methodology
    1. Market Definition and Segmentation
    2. Assumptions and Acronyms
    3. Research Objective
    4. Research Methodology
  2. Executive Summary
  3. Industry Value Chain Analysis
  4. Market Dynamics
    1. Drivers
    2. Challenges
    3. Trends
    4. Opportunities
  5. Regulatory & Standards Landscape
  6. Industry Risk Analysis
  7. Industry Growth Outlook
  8. Growth Opportunity Analysis for Business Development
  9. Impact of COVID-19 on the Global CDK 4/6 Inhibitor Drugs Market
  10. Average Pricing Analysis
  11. Comparative Analysis
  12. Competitive Landscape
  13. Product Pipeline Analysis
  14. Global CDK 4/6 Inhibitor Drugs Market
    1. By Value (USD Million)
    2. Global CDK 4/6 Inhibitor Drugs Market Segmentation Analysis 2020-2030
      1. By Drug Type
        1. Palbocilib (Ibrance)
        2. Ribocilib (Kisqali)
        3. Abemaciclib (Verzenio)
      2. By Patient
        1. Pre-Menopausal
        2. Post-Menopausal
        3. Others
      3. By End-Users
        1. Hospitals
        2. Clinics
        3. Research Laboratories
        4. Retail Pharmacies
      4. By Region
        1. North America
        2. Europe
        3. Asia Pacific
        4. Latin America
        5. Middle East & Africa
  15. North America CDK 4/6 Inhibitor Drugs Market
    1. Market by Value (USD Million)
      1. By Drug Type
        1. Palbocilib (Ibrance)
        2. Ribocilib (Kisqali)
        3. Abemaciclib (Verzenio)
      2. By Patient
        1. Pre-Menopausal
        2. Post-Menopausal
        3. Others
      3. By End-Users
        1. Hospitals
        2. Clinics
        3. Research Laboratories
        4. Retail Pharmacies
      4. By Country
        1. United States
        2. Canada
  16. Europe CDK 4/6 Inhibitor Drugs Market
    1. Market by Value (USD Million)
      1. By Drug Type
      2. By Patient
      3. By End-Users
      4. By Country
        1. United Kingdom
        2. Germany
        3. France
        4. Italy
        5. Spain
        6. Russia
        7. Netherlands
        8. Rest of Europe
  17. Asia Pacific CDK 4/6 Inhibitor Drugs Market
    1. Market by Value (USD Million)
      1. By Drug Type
      2. By Patient
      3. By End-Users
      4. By Country
        1. China
        2. India
        3. Japan
        4. South Korea
        5. Singapore
        6. Australia
        7. Rest of Asia Pacific
  18. Latin America CDK 4/6 Inhibitor Drugs Market
    1. Market by Value (USD Million)
      1. By Drug Type
      2. By Patient
      3. By End-Users
      4. By Country
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  19. Middle East & Africa CDK 4/6 Inhibitor Drugs Market
    1. Market by Value (USD Million)
      1. By Drug Type
      2. By Patient
      3. By End-Users
      4. By Country
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa

Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved